Podcasts about antibiotic resistance

You ever wonder why you can't eat just one chip? Or why chicken tastes different than it did decades ago? In this episode, I break down how the food industry engineered salt, sugar and fat to hit your brain's “bliss point,” how fast food reshaped American farming, and why profit became more important than public health. From factory-raised chickens to feedlot beef to grocery store manipulation, we're unpacking how the system was built—and what you can actually do about it. Spoiler: it's not a willpower problem. It's a design problem.IntroFoodSalt, Sugar, Fat and the Bliss PointSoda: The Original Thirst TrapHow fast food rewired American farmingProfitsWhat we can actually do as consumers?Music by Loghan LongoriaFollow us on instagram: Sergio Novoa My Limited View PodResources & Research:1. Moss, Michael. Salt Sugar Fat: How the Food Giants Hooked Us. Random House, 2013. Key themes summarized at LifeClub.org. 2. Summary of processed food engineering and industry tactics at BooksThatSlay.com. 3. Overview of addictive design and ingredient roles at SoBrief.com. 4. Discussion of food companies prioritizing taste over health in processed products. 5. Reporting on antibiotic use and public health risks in livestock farming. 6. Advocacy overview of factory farming, antibiotics, and health impacts.

Explore how poultry farming pollutes ecosystems, spreads backyard neglect, and reveals the darker side of "sustainable" animal agriculture. #ChickenFarming #EcoVeganism #FactoryFarming #HealthTalks

In 1928, a chance contaminant in Scottish physician Alexander Fleming's lab experiment led to a discovery that would change the field of medicine forever: penicillin. Since then, penicillin and other antibiotics have saved millions of lives. With one problem: the growing threat of antibiotic resistance. Today on Short Wave, host Regina G. Barber talks to biophysicist Nathalie Balaban about the conundrum — and a discovery her lab has made in bacteria that could turn the tides.Check out our episodes on extreme bacteria in Yellowstone and the last universal common ancestor. Interested in more science behind our medicines? Email us your question at shortwave@npr.org.Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.This episode was produced by Berly McCoy, edited by our showrunner Rebecca Ramirez and fact checked by Tyler Jones. Jimmy Keeley was the audio engineer. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

The rise of antibiotic resistance is threatening millions of lives worldwide, but “unconventional” Australian research could make obsolete medications effective again. Data released by the World Health Organization (WHO) has found that some of the most common illnesses in the world are becoming more resistant to treatment every year. Dr Maud Eijkenboom says the current approach of developing new antibiotics is losing the battle against ever-evolving viruses and bacteria. After her son struggled with a resistant disease, Dr Eijkenboom set on her own path to discover a better way eradicate the rising wave of lethal pathogens. In 2021, she founded Lixa, a Perth-based biotech company receiving international support for its “game-changing” research. In this edition of Weekend One on One, she speaks with SBS's Cameron Carr about the impact of her research, and started by explaining what Lixa is all about.

The Interdisciplinary Meeting of Antimicrobial Resistance and Innovation has launched! The first version of IMARI brought together researchers, clinicians, industry leaders and policymakers to address one of the greatest challenges in modern medicine: antimicrobial resistance" Check the highlights at IMARI.org and prepare for IMARI 2017 from January 27-29, 2027! The inaugural amazing conference took place in Las Vegas. This is the forst time that ASM and IDSA collaborate together in a scientific meeting. One of the sessions involved an unprecedent collaboration between two journals AAC and JID published by each society. To celebrate this achievement we had a session of the best AMR papers of 2025 for AAC and JID. This session will be presented here as apart of our series.  Watch this episode: https://youtu.be/XRYl7863z34 Objectives: - Review the best papers and topics of AMR in 2025 form AAC and JID. - Discuss the context of each finding and contributions to the AMR community - Elaborate on the implications for AMR, novelties and how the field is advancing. Guests:  - Ayesha Khan, Ph.D.  Assistant Professor, Pathology & Laboratory Medicine and Associate Director, Division of Clinical Microbiology Biomedical & Translational Research Track. Principal Investigator, UC3P UCI Prime Pre-Health Pathways Program. - Madison Stellfox, M.D. Ph.D. Assistant Professor of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.  Links:  Links: AAC A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp. https://doi.org/10.1128/aac.01627-24 JID Ampicillin/Sulbactam in Combination with Ceftazidime/Avibactam Against Metallo-β-Lactamase-Producing Carbapenem-Resistant Acinetobacter baumannii: A Genomics-Informed Mechanism-based model https://doi.org/10.1093/infdis/jiaf567 AAC Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors https://doi.org/10.1128/aac.01614-24 JID Daptomycin-Loaded Nanocarriers Facilitate Synergistic Killing of Methicillin-Resistant Staphylococcus aureus via Lipid-Mediated Interactions and Targeting https://doi.org/10.1093/infdis/jiaf492 AAC Amoxicillin-non-susceptible Streptococcus pneumoniae causing invasive pneumonia: serotypes, clones, and clinical impact https://doi.org/10.1128/aac.00237-25 JID Blood Cultures Contain Populations of Genetically Diverse Candida albicans Strains that May Differ in Echinocandin Tolerance and Fitness https://doi.org/10.1093/infdis/jiaf495 AAC Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains https://doi.org/10.1128/aac.00137-25 JID Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates https://doi.org/10.1093/infdis/jiae438 AAC Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice https://doi.org/10.1128/aac.01310-24 JID The Changing Paradigm in Infectious Diseases—Host-Directed Medicine: Implications for the Next Generation of ID Physicians https://doi.org/10.1093/infdis/jiaf497 JID Triggering Toll-Like Receptor 5 Signaling During Pneumococcal Superinfection Prevents the Selection of Antibiotic Resistance https://doi.org/10.1093/infdis/jiae239 IMARI Conference This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at https://asm.org/aac.  If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit https://asm.org/joinasm to sign up. Visit https://asm.org/aac to browse issues and/or submit a manuscript. Follow Cesar on twitter at https://twitter.com/SuperBugDoc for AAC updates. 

Antibiotics have long served as a foundation of modern veterinary medicine, especially in livestock animals. Yet a growing public health threat looms as bacteria evolve to evade these vital drugs. A new study from the University of Kentucky's Martin-Gatton College of Agriculture, Food and Environment reveals that antibiotic resistance in cattle-associated bacteria could have far-reaching implications for human, animal and environmental health. Dr. Greg talks with Yosra Helmy, associate professor of One Health and Infectious Diseases in the Department of Veterinary Science and One Health Center researcher, who led the study.

The Predator's Playbook: How To Identify And Prevent Child Sexual AbuseChild abuse is a sobering reality often perpetrated by trusted individuals rather than strangers. To successfully exploit a child, predators rely on a specific playbook to gain access, trust, and secrecy. Our expert this week explains how parents can help dismantle these opportunities without needing to resort to overprotective parenting styles.Guests: Dr. Bronwen Carroll, pediatric emergency medicine physician, Boston Medical Center, assistant professor of pediatrics, Boston UniversityHost: Elizabeth WestfieldProducer: Polly Hansen  Why Are Kidney Stones Skyrocketing In Young Girls?Kidney stones, historically associated with middle-aged men, are now being diagnosed at an increasing rate in young girls. Though stones can remain undetected for years, they often cause extreme pain and nausea once they move into the ureter. Our expert discusses treatment options and possible reasons we're seeing more cases in younger patients.  Guests: Dr. Greg Tasain, attending pediatric urologist, Children's Hospital of Philadelphia, professor of surgery, University of Pennsylvania Perelman School of Medicine  Host: Greg JohnsonProducers: Kristen Farrah Medical Notes: The Shocking Veteran Suicide Trends, The Best Time To Induce Labor, And The Mental Health Of College StudentsThe tides may finally be turning on veteran suicide. A new treatment for seizures may soon be possible without the need for invasive brain surgery. When it comes to inducing labor, success may be all in the timing. The stigma surrounding mental health on campus is fading. Host: Maayan Voss de Bettancourt Producer: Kristen Farrah Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Why Are Kidney Stones Skyrocketing In Young Girls?Kidney stones, historically associated with middle-aged men, are now being diagnosed at an increasing rate in young girls. Though stones can remain undetected for years, they often cause extreme pain and nausea once they move into the ureter. Our expert discusses treatment options and possible reasons we're seeing more cases in younger patients.  Guest: Dr. Greg Tasain, attending pediatric urologist, Children's Hospital of Philadelphia, professor of surgery, University of Pennsylvania Perelman School of Medicine Host: Greg Johnson  Producers: Kristen Farrah Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode on “Public awareness of urinary tract infections and the fight against antimicrobial resistance”, Assoc. Prof. Z. Tandoğdu (TR) is joined by Prof. G. Bonkat (CH) and Mrs. J.M. Meijlink (NL) to address one of today's most pressing global health challenges. UTIs are among the most common bacterial infections worldwide, yet they are often wrongly perceived as minor conditions. This misconception can lead to overuse or misuse of antibiotics, fuelling the rapid spread of antimicrobial resistance.Prof. Bonkat shares insights from the EAU Guidelines on how responsible prescribing and clinical practice can help prevent unnecessary antibiotic use. Mrs. Meijlink shares the patient perspective, stressing the importance of accurate information and clear communication between doctors and patients.Together, the speakers explore how awareness campaigns, education, and collaboration across healthcare and patient communities are essential to reducing the burden of UTIs. They emphasise that antimicrobial resistance already causes millions of deaths each year and requires urgent, coordinated action.The discussion highlights practical steps for clinicians and patients alike, while reminding listeners that sustainable management of UTIs depends on both medical expertise and active public involvement.AcknowledgmentThis activity is supported by an educational grant from our industry partner - GSK, with no involvement in the programme or speaker selection.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Everyday chemicals from pesticides, plastics, and flame retardants act like hidden antibiotics in your gut, killing beneficial bacteria that support digestion, immunity, and metabolic health Researchers identified 168 common industrial and agricultural chemicals that slowed or stopped the growth of healthy gut microbes, including key species that protect your gut lining and reduce inflammation Some gut bacteria exposed to these chemicals became more resistant to antibiotics, which weakens your future ability to fight infections when antibiotics are truly needed Even low, daily exposures from food, water, air, and household items were enough to disrupt gut bacteria, meaning chronic symptoms like bloating, fatigue, and food sensitivities often trace back to environmental sources, not just diet Reducing chemical exposure while actively supporting gut bacteria helps restore microbial balance, strengthen your gut barrier, and improve energy, immune resilience, and overall health from the inside out

It's getting harder to avoid antibiotics in our food supply.

The benefits of sauna and sunlight during winter monthsApplied Behavioral Analysis in autism treatmentWhat are good supplements to take for HPV virus?

I was diagnosed with follicular lymphoma, but my symptoms may be caused by something else, per my oncologistI've been taking acidophilus and eating yogurt, but still have diarrhea for the last five months since taking a round of antibioticsThe consequences of antibiotic useMy carotid artery intima-media thickness shows higher than normal thickness. Should I be concerned?

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the exciting, yet challenging, landscape of gene therapies and their potential to revolutionize healthcare. Recent scientific advancements have pushed the boundaries of what's possible, offering potential lifetime cures for diseases once considered incurable. However, this breakthrough comes with a significant economic caveat: the staggering cost of these therapies, often ranging between $3 to $4 million per patient. This price tag presents a formidable challenge to current healthcare infrastructures.The disconnect between these innovative treatments and existing payment systems is evident in what industry experts term the "$4 million payment problem." Therapies like Lenmeldy and Hemgenix highlight this issue. Lenmeldy, for instance, can prevent metachromatic leukodystrophy with a single infusion priced at $4.25 million, while Hemgenix offers a cure for hemophilia B at $3.5 million. These therapies effectively convert lifelong treatment costs into a singular, substantial payment, challenging traditional insurance models that are built to spread costs over time.The primary obstacle is not the efficacy of these treatments but rather the financial and logistical infrastructures needed to support them. The current insurance model is ill-equipped to handle such large, one-time payments. Employers who often provide health insurance face a dilemma: investing millions in curing an employee who might leave the company shortly after receiving treatment could result in significant financial risk and disincentivizes employers from covering such therapies.Enter Aradigm Health, which has emerged as a potential solution to this conundrum. Aradigm aims to create an "infrastructure layer" specifically for these high-cost cures. With $20 million in funding backing their initiative, Aradigm seeks to pool financial risk across multiple employers, thus mitigating the impact of substantial individual claims. Their model involves employers contributing a fixed monthly fee into a shared fund that covers these expensive treatments when needed. This approach distributes financial volatility across a broader base rather than placing it on individual employers.Aradigm's strategy is not only about financial solutions but also about streamlining logistical complexities associated with delivering gene therapies. Their patient journey management includes coordinating with biotech companies for manufacturing schedules, arranging travel and accommodation for patients and families, and ensuring seamless insurance paperwork handling. This comprehensive support system reduces barriers that often delay or disrupt treatment delivery.Operating as a public benefit corporation with a "cost-plus" model, Aradigm ensures that any surplus from lower-than-expected claims is returned to employers rather than kept as profit. This aligns incentives towards patient care rather than profit maximization. Their approach highlights a critical need within the biotech and pharmaceutical industries: developing adaptable infrastructures that align with rapid scientific advancements.Meanwhile, Amgen has secured significant ground in 2023 with its second FDA approval for Uplizna in treating generalized myasthenia gravis—a chronic autoimmune neuromuscular disorder characterized by varying degrees of skeletal muscle weakness. Uplizna's mechanism involves targeting CD19 on B cells implicated in autoimmune diseases' pathogenesis. This expansion marks an advancement in therapeutic options for patients and underscores Amgen's growing footprint in treating complex autoimmune conditions.GlaxoSmithKline has also made headlines with Blujepa, marking it as the first new class of antibiotics for gonorrhea in over three decades while receiving approval for treating uncomplicSupport the show

The new National Food Council meets for the first time to start developing Australia's food strategy, an SA company launches a new non-terrestrial 5G network for industries such as farming and mining, and SA researchers win a grant to study how soil microbes could help tackle antibiotic resistance.

Pain relief medications like acetaminophen and ibuprofen are staples in everyday care—but emerging research suggests they may play a role in antibiotic resistance. This episode reviews recent findings, explores how these common drugs may influence bacterial response to antibiotics, and highlights pharmacist‑specific considerations. You will walk away with practical insights to support informed medication use and strengthen antibiotic stewardship.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTHunter O. Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship Coordinator, SSM HealthAdjunct Clinical Assistant Professor, University of Kansas School of PharmacyRachel Maynard has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated.Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe emerging evidence on how common OTC pain medications may influence antibiotic resistance.2. Identify pharmacist strategies to optimize analgesic and antibiotic use while supporting antimicrobial stewardship.0.05 CEU/0.5 HrUAN: 0107-0000-25-372-H01-PInitial release date: 12/8/2025Expiration date: 12/8/2026Additional CPE details can be found here.

Pain relief medications like acetaminophen and ibuprofen are staples in everyday care—but emerging research suggests they may play a role in antibiotic resistance. This episode reviews recent findings, explores how these common drugs may influence bacterial response to antibiotics, and highlights pharmacist‑specific considerations. You will walk away with practical insights to support informed medication use and strengthen antibiotic stewardship.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsHunter O. Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship Coordinator, SSM HealthAdjunct Clinical Assistant Professor, University of Kansas School of PharmacyRachel Maynard has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe emerging evidence on how common OTC pain medications may influence antibiotic resistance.2. Identify pharmacist strategies to optimize analgesic and antibiotic use while supporting antimicrobial stewardship.0.05 CEU/0.5 HrUAN: 0107-0000-25-372-H01-PInitial release date: 12/8/2025Expiration date: 12/8/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we dive into some of the most significant and exciting advancements shaping the industry.Let's start with a breakthrough coming out of recent clinical trials. A novel approach to treating Alzheimer's disease is making waves. Researchers have been focusing on a monoclonal antibody designed to target amyloid-beta plaques in the brains of patients suffering from this debilitating condition. The latest Phase 3 trial results have shown a promising reduction in cognitive decline among participants, offering a glimmer of hope for millions affected by Alzheimer's worldwide. The study, conducted over 18 months, involved more than 1,500 patients and demonstrated a statistically significant slowing of disease progression compared to placebo. This could mark a pivotal moment in Alzheimer's treatment, shifting the paradigm from symptomatic relief to disease modification.In regulatory news, the FDA has granted approval to a new gene therapy for hemophilia B. This therapy, developed using cutting-edge CRISPR technology, offers a potential cure for patients who have long relied on regular infusions to manage their bleeding disorder. By directly editing the genes responsible for clotting factor production, this therapy can potentially provide long-term relief with just a single administration. The approval follows extensive clinical trials that showed sustained increases in clotting factor levels and a dramatic reduction in bleeding episodes among participants. This development not only underscores the growing impact of genomic medicine but also highlights the regulatory body's commitment to advancing innovative treatments that meet unmet medical needs.Shifting focus, there's an intriguing trend emerging in oncology drug development. The industry is increasingly adopting personalized medicine approaches, tailoring treatments based on individual genetic profiles. This shift is particularly evident in the rise of targeted therapies and combination regimens designed to tackle cancer at its genetic roots. A recent study demonstrated how combining targeted therapies with immune checkpoint inhibitors can enhance treatment efficacy in certain types of cancer, such as melanoma and non-small cell lung cancer. By understanding the specific mutations driving tumor growth and leveraging the body's immune response, these combinations are setting new standards for cancer care.In another significant development, researchers have unveiled promising results from an innovative mRNA vaccine trial aimed at combating infectious diseases beyond COVID-19. The technology, which gained prominence during the pandemic, is now being applied to other viral threats like influenza and RSV. Early-phase clinical trials have shown robust immune responses and favorable safety profiles, suggesting mRNA vaccines could soon revolutionize how we approach vaccination for a variety of pathogens. This versatility and rapid development timeline make mRNA platforms particularly attractive for addressing emerging infectious diseases swiftly.Meanwhile, a new study has raised awareness about antibiotic resistance—a growing concern globally. Scientists have developed an advanced diagnostic tool capable of rapidly identifying bacterial infections and their resistance profiles within hours instead of days. This innovation can significantly impact how clinicians prescribe antibiotics, ensuring targeted treatments that minimize resistance development. By providing real-time insights into bacterial genetics and resistance mechanisms, this tool empowers healthcare providers to make informed decisions that preserve antibiotic efficacy for future generations.Lastly, let's toSupport the show

The use of antibiotics in treating livestock in the UK has fallen, according to a new report published by the Veterinary Medicines Directorate, which is a government agency. Using high levels of antibiotics in farming can lead to people developing resistance to life-saving antibiotics.The Alliance to Save Our Antibiotics, which was set up to reduce antibiotic use in farm animals, through better livestock husbandry, has just published its own report into antibiotic drug use, particularly in pigs and poultry. It says poultry producers are still using too many ionophores, a kind of medicine to treat parasites, and it wants ionophores to be classified as antibiotics.All week, we're taking a global perspective on farming as delegates at COP 30 in Brazil discuss food production and reducing its impact on the climate. One UK businessman has come up with a system for harvesting the straw left over from rice. It's usually allowed to rot in the fields, or it's burnt but Craig Jamieson has developed a special machine to harvest it and it's now being trialled in the Philippines.We celebrate the farm business that's won the Future Farming award in the BBC's Food and Farming Awards.Presenter: Anna Hill Producer: Rebecca Rooney

Sepsis and bloodstream infections (BSIs) are common and cause millions of deaths each year, with a disproportionate burden in low-income and middle-income countries. Tune in to learn from Jasmine R. Marcelin, MD, FACP, FIDSA, how inadequate antibiotic coverage can be linked to increased mortality and length of stay and how unnecessary broad-spectrum antibiotics can drive antimicrobial resistance. Topics covered include:The worldwide burden of sepsis and BSIsThe ongoing threat of antimicrobial resistanceUS and global health disparities in sepsis, BSI, and antimicrobial resistanceBarriers toward optimizing antibiotic use in BSIsPresenter:Jasmine R. Marcelin, MD, FACP, FIDSAAssociate Professor, Infectious DiseaseAssociate Medical Director, Antimicrobial Stewardship ProgramVice Chair for Belonging and Community Engagement, Department of Internal MedicineCo-Director, Digital Innovation & Social Media Strategy, Division of Infectious DiseasesUniversity of Nebraska Medical CenterOmaha, NebraskaLink to full program and downloadable slides:https://bit.ly/4inoXCxGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Unnecessary broad-spectrum antibiotics can drive antimicrobial resistance and cause adverse events, whereas inadequate antibiotic coverage is linked to increased mortality and length of stay for patients with bloodstream infections (BSIs). Listen now to learn from Jose Alexander, MD, D(ABMM), CIC, FCCM, SM/MB(ASCP), how to use rapid genotypic and phenotypic antimicrobial susceptibility testing results to inform antibiotic selection for patients with gram-negative BSIs. Topics covered include:Typical patterns of intrinsic antibiotic susceptibility and resistance in EnterobacteralesMechanisms of resistance in gram-negative bacteriaGenotypic rapid diagnostic tests for BSIsResistance markers for earlier targeted therapyRapid phenotypic antimicrobial susceptibility test platforms for blood culturesPresenter:Jose Alexander, MD, D(ABMM), CIC, FCCM, SM/MB(ASCP)Medical and Public Health MicrobiologistMedical and Technical Director of MicrobiologyAdventHealthOrlando, FloridaLink to full program and downloadable slides:https://bit.ly/4inoXCxGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rapid phenotypic antimicrobial susceptibility testing (AST) significantly reduces time to actionable results and can improve antibiotic decision-making for patients with bloodstream infections. Listen in to learn from Michael P. Veve, PharmD, MPH, how to optimally integrate rapid phenotypic AST into clinical practice, including incorporation into your existing antimicrobial stewardship workflow. Topics covered include:Considerations for implementationDecision-making steps for implementationThe role of antimicrobial stewardship programs in AST workflowPresenter:Michael P. Veve, PharmD, MPHClinical Associate ProfessorDepartment of Pharmacy PracticeEugene Applebaum College of Pharmacy and Health SciencesWayne State UniversityClinical Pharmacy Specialist, Infectious DiseaseHenry Ford HospitalDetroit, MichiganLink to full program and downloadable slides:https://bit.ly/4inoXCxGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Antibiotic resistance is a rapidly growing global threat, driven by misused medications and the natural evolution of bacteria. Modern technologies such as AI-guided phage therapy and AMR surveillance are opening new pathways to detect, target, and treat resistant infections more precisely. Tackling this crisis, however, requires a unified “One World” approach where countries share data, resources, and innovations to protect human, animal, and environmental health. I'm thrilled to be joined by two of our biology students, Maisie and Tilly who will have conducted and will share their own research into this fascinating subject.

Dr Megan Dempster, a researcher at Wits’ Vaccines & Infectious Disease Analytics unit, speaks to John Maytham about a study that found that two types of bacteria are responsible for or more than half the infections that kill newborns and infants in Soweto. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Matters Microbial #112: Bacterial Size, Stress, and Antibiotic Resistance October 17, 2025 Today Dr. Petra Levin, the George and Irene Freiberg Professor of Biology at Washington University in St. Louis joins the #QualityQuorum to discuss her work with bacterial cell size, environmental stress on bacteria, and antibiotic resistance. Host: Mark O. Martin Guest: Petra Levin Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode An overview of the periplasm, found in Gram negative bacteria. An overview of beta-lactam antibiotics. The field of quantitative microbiology. An overview of B. subtilis.  An overview of E. coli.  An overview of Klebsiella.  The biography of Barbara McClintock, “A Feeling for the Organism.” A video explanation of the lac operon of E. coli. The LTEE program (Long Term Evolution Experiment) founded by Dr. Rich Lenski. The nomenclature of monoderm and diderm bacteria. A video explanation of peptidoglycan in bacteria. Penicillin binding proteins (PBP) and antibiotic resistance. A video about cell division in E. coli. A famous article coauthored by Dr. Elio Schaechter that describes cell growth and cell size in bacteria. A related article by Dr. Levin and colleagues. An overview of ESKAPE bacteria. An article from Dr. Levin's research group describing the relationship between pH and antibiotic resistance. An article about persister cells and their relevance to antibiotic resistance. Dr. Levin's faculty website. Dr. Levin's very interesting laboratory website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Professor Christian Schulz from the Medical Department 2, LMU Munich, Munich, Germany on the paper "Helicobacter pylori antibiotic resistance: a global challenge in search of solutions" published in paper copy in Gut in October 2025. Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://spoti.fi/3Ifxq9p).

Send us a textDrug-resistant germs are hidden killers in more than one way. Not only are the microbes invisible to the human eye, in many places, they're invisible because people simply are not looking for them systematically.Doctors often do not know what infections their patients have and treat them based on best guesses, which allows for ineffective treatments and exacerbates drug resistance. Policymakers don't know which infections are most common among populations and cannot make informed decisions about needed treatments or vaccines.This is a major problem across Africa and a new report shows just how complex the problem is.The Mapping AMR and Antimicrobial use Partnership (MAAP), which included the One Health Trust as well as the African Society for Laboratory Medicine; Africa CDC; the East, Central, and Southern Africa Health Community; Innovative Support to Emergencies, Diseases, and Disasters, a nonprofit focused on technology and communication;  the clinical research group IQVIA; and the West African Health Organization, collected data from laboratories from 14 countries in Africa (Burkina Faso, Cameroon, Gabon, Ghana, Kenya, Eswatini, Malawi, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe). “The study revealed significant gaps in bacteriology testing capacities,” the group, whose work was paid for by the UK government's Fleming Fund, wrote in PLoS Medicine.It's the biggest survey yet of testing for antimicrobial resistance – AMR or drug resistance – in Africa.Among the gaps: too little testing overall, a lack of laboratory capacities, and poor coordination and analysis of records. Many records were kept only on paper, which made them almost impossible to access.None of this surprises Dr. Sabiha Essack, South African Research Chair in Antibiotic Resistance and One Health and Professor in Pharmaceutical Sciences at the University of KwaZulu-Natal. In an ideal world, she says, a doctor, nurse or other professional should see a patient, test them to see what specific microbe is causing an infection, check to see which drugs will successfully fight that germ, and then treat the patient accordingly.Cheap point-of-care tests should be available everywhere and the results of those tests should be entered into systems that officials can use to make policy decisions, she says. Listen as she tells One World, One Health host Maggie Fox other ways to improve our knowledge about the drug-resistant infections that lurk out there. Want to know more? You can find One World, One Health episodes on drug-resistant infections in cancer patients; superbugs and microplastics; the personal toll of antibiotic resistance; one woman's antibiotic resistance nightmare; how to prevent drug resistance, and more.

Pippa speaks to Dr Elloise du Toit of the University of Cape Town about antibiotic resistance. Lunch with Pippa Hudson is CapeTalk’s mid-afternoon show. This 2-hour respite from hard news encourages the audience to take the time to explore, taste, read and reflect. The show - presented by former journalist, baker and water sports enthusiast Pippa Hudson - is unashamedly lifestyle driven. Popular features include a daily profile interview #OnTheCouch at 1:10pm. Consumer issues are in the spotlight every Wednesday while the team also unpacks all things related to health, wealth & the environment. Thank you for listening to a podcast from Lunch with Pippa Hudson Listen live on Primedia+ weekdays between 13:00 and 15:00 (SA Time) to Lunch with Pippa Hudson broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/MdSlWEs or find all the catch-up podcasts here https://buff.ly/fDJWe69 Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Listen in as Dr Trevor Van Schooneveld explores rapid syndromic testing for gastrointestinal and joint infections and discusses how to apply best practices for diagnostic and antimicrobial stewardship in syndromic testing. Topics covered include: Who should be tested for infectious diarrheaTypes of gastrointestinal syndromic panelsTypes of syndromic panels for joint infectionsReal-world applications for joint syndromic panelsPresenters: Trevor Van Schooneveld, MDProfessor, Division of Infectious DiseasesMedical Director, Antimicrobial Stewardship ProgramDepartment of Internal MedicineUniversity of Nebraska Medical CenterOmaha, NebraskaLink to full program: https://bit.ly/4mHOTtWGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

Matters Microbial #104: Antibiotic “Tolerance” and Biofilms August 21, 2025 Today, Dr. Boo Shan Tseng, Associate Professor at the University of Nevada Las Vegas School of Life Sciences, joins the #QualityQuorum to discuss bacterial biofilms and antibiotic tolerance.  Host: Mark O. Martin Guest: Boo Shan Tseng Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode A video overview of biofilms. A comprehensive review article on biofilms. An article describing the impact biofilms have on disease. An article describing the impact of biofilms on implanted medical devices. A link to the Center for Biofilm Engineering at Montana State University that has MANY links of interest. An overview of biofilm development. An overview of confocal laser microscopy. Studying biofilms in flow cells. An article about the role proteins play in biofilm formation, which intersects with the Tseng group's research. The technique of single cell RNA seq. The technique of mRNA-FISH. An article about porins in bacteria, and how that can relate to antibiotic resistance. An article by Dr. Tseng and coworkers on the eDNA and biofilms discussed today. A lovely video of Dr. Tseng talking about the research she and her colleagues carry out in the laboratory. Dr. Tseng's biography from the American Society for Microbiology. Dr. Tseng's laboratory group website with wonderful links and images. Dr. Tseng's faculty website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

Mycoplasma genitalium or Mgen is an STI most people don't know exists - and yet it's super common and can be very difficult to treat due to antibiotic resistance. We chat to Professor Catriona Bradshaw covering everything from stats and symptoms, to getting tested and treatments.DM us your thoughts, questions, topics, or to just vent at @triplejthehookup on IG or email us: thehookup@abc.net.auThe Hook Up is an ABC podcast, produced by triple j. It is recorded on the lands of the Wurundjeri people of the Kulin nation. We pay our respects to elders past and present. We acknowledge Aboriginal and Torres Strait Islander peoples as the First Australians and Traditional Custodians of the land where we live, work, and learn.

HIV, superbugs, and standards—oh my! In this episode of Absolute Gene-ius, we explore the frontier of infectious disease research with Dr. Jesús Mingorance, researcher at Hospital Universitario La Paz in Madrid. His research is translational and uses digital PCR, qPCR, sequencing, and more.Dr. Mingorance walks us through his application of ultra-sensitive PCR methods to track HIV-2 viral loads—particularly in challenging cases where standard assays fall short. He shares how digital PCR enabled detection in samples where conventional tests failed, and how it's becoming essential for assay calibration and microbial quantification. He also dives into the endemic challenges of carbapenem-resistant Klebsiella pneumoniae in hospitals, revealing the clinical and epidemiological importance of quantifying pathogen load within the microbiome.In the career corner, Dr. Mingorance recounts his unconventional journey—from humanities student to biologist inspired by a single sentence about DNA. With humor and honesty, he reflects on the patience needed in science, the value of good questions, and the importance of mentoring new scientists. “Biology is beautiful,” he reminds us. We agree.Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

Listen in as Michael Satlin, MD, MS, FIDSA,explores rapid syndromic testing for bloodstream infections and discusses how to apply best practices for diagnostic and antimicrobial stewardship in syndromic testing.Topics covered include:Types of upper and lower respiratory infection panelsConsiderations for when to use respiratory syndromic testingHow to use syndromic testing to guide both therapy escalation and de-escalationHow syndromic testing fits in with traditional testing methods, such as culture, antimicrobial susceptibility testing, Gram stain, and BAL cell count Presenter:Michael Satlin, MD, MS, FIDSAAssociate Professor of Medicine and Pathology and Laboratory MedicineWeill Cornell MedicineNew York, New YorkLink to full program: https://bit.ly/3UAB1oUGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

One of the greatest medical breakthroughs of the twentieth century is set to become one of the biggest threats of the twenty-first - but what can be done to stem the rising tide of antibiotic resistance? In this episode, host Caroline Dodds Pennock speaks with Liam Shaw, biologist and author of Dangerous Miracle: A Natural History of Antibiotics – and How We Burned Through Them. From the miraculous discovery of penicillin to the industrial-scale production that changed healthcare and agriculture forever, Shaw takes us through the fascinating - and cautionary - story of these ‘fossil fuels of medicine.' Together, they explore when and how the threat of resistance emerged, the roles of Big Pharma and industrial farming in accelerating the crisis, and the parallels with climate change in how we've squandered a finite resource. But as MIT researchers recently announced a breakthrough with AI designing antibiotics for gonorrhoea and MRSA superbugs, Shaw also outlines clear roadmaps for the future - including bold proposals for transforming the way we develop, patent and pay for antibiotics. If you'd like to become a Member and get access to all our full conversations, plus all of our Members-only content, just visit intelligencesquared.com/membership to find out more. For £4.99 per month you'll also receive: - Full-length and ad-free Intelligence Squared episodes, wherever you get your podcasts - Bonus Intelligence Squared podcasts, curated feeds and members exclusive series - 15% discount on livestreams and in-person tickets for all Intelligence Squared events  ...  Or Subscribe on Apple for £4.99: - Full-length and ad-free Intelligence Squared podcasts - Bonus Intelligence Squared podcasts, curated feeds and members exclusive series … Already a subscriber? Thank you for supporting our mission to foster honest debate and compelling conversations! Visit intelligencesquared.com to explore all your benefits including ad-free podcasts, exclusive bonus content and early access. … Subscribe to our newsletter here to hear about our latest events, discounts and much more. https://www.intelligencesquared.com/newsletter-signup/ Learn more about your ad choices. Visit podcastchoices.com/adchoices Learn more about your ad choices. Visit podcastchoices.com/adchoices

Listen in as Dr Emily Heil explores rapid syndromic testing for bloodstream infections and discusses how to apply best practices for diagnostic and antimicrobial stewardship in syndromic testing.Topics covered include:The importance of good blood culture practices and finding the balance between overuse and underuseBlood culture improvement programsThe utility of rapid diagnostic testsResistance markers for earlier targeted therapyPresenters:Emily Heil, PharmD, MS, BCIDP, AAHIVPProfessorDepartment of Practice, Sciences, and Health Outcomes ResearchUniversity of Maryland School of PharmacyBaltimore, MarylandLink to full program: https://bit.ly/45Ajz92Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, we review how genomics is being used to fight against antimicrobial resistance (AMR). From outbreak tracking to detecting resistance genes, genomic tools are transforming how we understand, diagnose, and manage infectious threats. About our Guest: Professor Sabiha Essack is a seasoned researcher and a former Wellcome Trust Research Fellow who completed research towards her PhD in Pharmaceutical Microbiology at St Bartholomew's and the Royal London School of Medicine and Dentistry in the United Kingdom. She currently serves as the South African Research Chair (SARChI) in Antibiotic Resistance and One Health and a Professor in Pharmaceutical Sciences at the University of KwaZulu-Natal (UKZN). View her inspiring and versatile biography HERE! WE'D LOVE YOUR FEEDBACK ON THIS EPISODE – Visit the Microbe Mail website to sign up for updates Follow on:Instagram: Microbe_MailX/Twitter: @microbemailFacebook: MicrobeMailTiktok: @microbe.mailWatch this episode on our new YouTube channel: Microbe MailE-mail us: mail.microbe@gmail.com

In this second episode on antibiotics, the Infectious Minds duo explores an unintended, and occasionally terrifying consequence of these life-saving drugs, antibiotic resistance. What exactly is antibiotic resistance? How did it arise? And what kind of microbial “monsters” are we now up against? This episode unpacks the fundamental science behind one of medicine's most urgent and literally evolving threats.

AMR Initiative Rwanda is a nonprofit organization implementing the One Health approach to prevent, mitigate, and control the spread of resistant microorganisms, while ensuring the availability of safe, effective, and high-quality antimicrobials, and promoting their prudent and rational use in Rwanda. Joining me today from Kigali, Rwanda is Marcel Ishimwe. Marcel is a pharmacist and the founder and CEO of AMR Initiative Rwanda.

What percentage of meat samples test positive for drug residue violations?

In episode 14 of this season we are joined by Cóilín Nunan, to discuss the growing global threat of antibiotic resistance and how the overuse of antibiotics in animal agriculture is contributing to this silent pandemic.Cóilín is the Policy and Science Manager of the Alliance to Save Our Antibiotics, an alliance of seventy-one member organisations campaigning against the overuse of antibiotics in animal farming.Cóilín breaks down how antibiotics are used not only to treat infections but also prevent disease in crowded, unsanitary conditions. This results in a breeding ground for drug-resistant bacteria that can affect both animals and humans.This discussion highlights why we view the shift to plant-based diets as one of the key ways to drive down this overuse, and protect antibiotics for when we actually need them within healthcare.Please share this episode widely to help raise awareness and be part of the change towards a better future for all.To find out more about the alliance's work and to get involved: https://www.saveourantibiotics.org/

The lack of precision in identifying the infections that cause interstitial cystitis (IC), chronic bladder infections, prostate infections, chronic sinus infections, and more has led to mistreatment, ongoing suffering, and ineffective care. But that's changing thanks to MicroGenDX, a leader in molecular diagnostics.   Key Takeaways To Tune In For: (01:09) Introducing MicroGen DX (06:11) The Importance of Evidence-Based Medicine (10:30) Real-World Impact of MicroGen Testing (18:05) Antibiotic Resistance and Its Consequences (24:06) Genotypic vs. Phenotypic Sensitivity (30:30) Navigating the Healthcare System     Resources talked about in this episode: Website: microgendx.com View and sign the petition to get the testing covered by insurance.

How does one transform a personal crisis into a groundbreaking business that has the potential to change lives? This question lies at the heart of this episode, as we explore the journey of entrepreneurship through the lens of resilience, innovation, and a relentless drive to make a difference.Our guest, Martha Carlin, transitioned from a career in accounting to founding BiotiQuest after her husband's early Parkinson's diagnosis. Motivated to find solutions outside traditional medicine, Martha uncovered the power of the microbiome and developed specialized probiotics, leveraging years of research and personal investment to help improve lives—including her husband's.This episode provides an inside look at Martha's incredible story, the unique science behind her products, and the significant challenges small health businesses face in the era of digital marketplace giants. It's a must-listen for anyone interested in health, entrepreneurship, or what it truly takes to pursue a mission-driven business in today's digital world. To get the latest from Martha Carlin, you can follow her below!https://www.linkedin.com/in/marthacarlin/https://biotiquest.com/ Sign up for Marcia's newsletter to receive tips and the latest on Angel Investing!Website: www.marciadawood.comLearn more about the documentary Show Her the Money: www.showherthemoneymovie.comAnd don't forget to follow us wherever you are!Apple Podcasts: https://pod.link/1586445642.appleSpotify: https://pod.link/1586445642.spotifyLinkedIn: https://www.linkedin.com/company/angel-next-door-podcast/Instagram: https://www.instagram.com/theangelnextdoorpodcast/TikTok: https://www.tiktok.com/@marciadawood

Broadcast from KSQD, Santa Cruz on 6-05-2025: Dr. Dawn answers an email about Dupuytren's contracture treatment, explaining her clinic experience using acupuncture anesthesia combined with Traumeel injections directly into palm nodules. She describes how this anti-inflammatory homeopathic compound, when injected into tendon sheaths, can break the cycle of fibrosis formation. Dr. Dawn explores fascinating quantum physics concepts involving collagen microstructure, water molecules, and hydrogen ion movement that may explain how acupuncture and homeopathy work through crystalline formations in collagen tubules. She discusses vitamin A's critical role in measles complications, explaining how deficiency dramatically increases risks of encephalitis and cardiac damage. Dr. Dawn covers two forms of dietary vitamin A - beta carotene from plants requiring enzymatic conversion, and vitamin A from animal products. She warns about vitamin A toxicity risks, particularly birth defects in pregnancy, while noting that typical American diets are adequate unlike vitamin D. Dr. Dawn examines vitamin D deficiency affecting 68% of children in a South Florida study, linking inadequate levels to bone health, immune function, and gut barrier integrity. She explains how vitamin D receptors throughout the body regulate cell differentiation, insulin secretion, and tight junction formation that prevents leaky gut syndrome. There are higher deficiency rates in darker-skinned populations and the historical context of rickets during industrialization when urban environments blocked sunlight exposure. She highlights revolutionary medical technology, the world's smallest pacemaker for newborns, half the size of a rice grain. This injectable device dissolves naturally after hearts self-repair, controlled by light-emitting patches communicating through the baby's skin. This breakthrough eliminates risky surgical removal procedures that caused complications, such as Neil Armstrong's death from pacemaker wire infections. Dr. Dawn discusses research showing shingles vaccination reduces dementia risk by 20%, particularly in women. She explains the natural experiment in Wales where universal healthcare created clear vaccination cutoff dates, allowing researchers to compare dementia rates. Dr. Dawn hypothesizes that cross-immunity against herpes viruses may protect brain tissue, noting even stronger protection with newer Shingrix vaccines compared to older Zostavax. She covers alarming increases in invasive Group A Streptococcus infections, with cases more than doubling from 2013 to 2022. Dr. Dawn explains how flesh-eating bacteria secretes enzymes that dissolve epithelial barriers in throats and lungs, allowing systemic spread that destroys tissue. She links rising cases to increasing diabetes and obesity rates that compromise immune function, noting devastating mortality rates approaching 10,000 deaths nationwide. Dr. Dawn celebrates a breakthrough antibiotic discovery of Lariocidin which works against highly drug-resistant bacteria through novel protein synthesis inhibition. She explains how antibiotic resistance spreads between bacterial species just like social media memes, emphasizing the urgent need for new treatments as 4 million people die annually from resistant infections. Dr. Dawn advocates for public funding since pharmaceutical companies avoid antibiotic development due to poor profit margins. She answers an email about Epstein-Barr virus detection, explaining its role in mononucleosis, Burkitt's lymphoma, and chronic fatigue syndrome. Dr. Dawn describes how EBV can remain dormant and reactivate during stress or immunocompromise, potentially triggering autoimmunity. She discusses similarities between EBV reactivation, Lyme disease, and long COVID, suggesting they may represent variations of the same inflammatory syndrome with different triggers. She explores the nocebo effect - how negative expectations worsen outcomes - and its amplification through social media. Dr. Dawn cites studies showing people warned about erectile dysfunction or altitude headaches experience these symptoms more frequently. She discusses recent phenomena like TikTok-induced tics and vaccine side effect amplification, warning that online health information creates dangerous nocebo loops that spread faster than traditional word-of-mouth.

Broadcast from KSQD, Santa Cruz on 6-05-2025: Dr. Dawn answers an email about Dupuytren's contracture treatment, explaining her clinic experience using acupuncture anesthesia combined with Traumeel injections directly into palm nodules. She describes how this anti-inflammatory homeopathic compound, when injected into tendon sheaths, can break the cycle of fibrosis formation. Dr. Dawn explores fascinating quantum physics concepts involving collagen microstructure, water molecules, and hydrogen ion movement that may explain how acupuncture and homeopathy work through crystalline formations in collagen tubules. She discusses vitamin A's critical role in measles complications, explaining how deficiency dramatically increases risks of encephalitis and cardiac damage. Dr. Dawn covers two forms of dietary vitamin A - beta carotene from plants requiring enzymatic conversion, and vitamin A from animal products. She warns about vitamin A toxicity risks, particularly birth defects in pregnancy, while noting that typical American diets are adequate unlike vitamin D. Dr. Dawn examines vitamin D deficiency affecting 68% of children in a South Florida study, linking inadequate levels to bone health, immune function, and gut barrier integrity. She explains how vitamin D receptors throughout the body regulate cell differentiation, insulin secretion, and tight junction formation that prevents leaky gut syndrome. There are higher deficiency rates in darker-skinned populations and the historical context of rickets during industrialization when urban environments blocked sunlight exposure. She highlights revolutionary medical technology, the world's smallest pacemaker for newborns, half the size of a rice grain. This injectable device dissolves naturally after hearts self-repair, controlled by light-emitting patches communicating through the baby's skin. This breakthrough eliminates risky surgical removal procedures that caused complications, such as Neil Armstrong's death from pacemaker wire infections. Dr. Dawn discusses research showing shingles vaccination reduces dementia risk by 20%, particularly in women. She explains the natural experiment in Wales where universal healthcare created clear vaccination cutoff dates, allowing researchers to compare dementia rates. Dr. Dawn hypothesizes that cross-immunity against herpes viruses may protect brain tissue, noting even stronger protection with newer Shingrix vaccines compared to older Zostavax. She covers alarming increases in invasive Group A Streptococcus infections, with cases more than doubling from 2013 to 2022. Dr. Dawn explains how flesh-eating bacteria secretes enzymes that dissolve epithelial barriers in throats and lungs, allowing systemic spread that destroys tissue. She links rising cases to increasing diabetes and obesity rates that compromise immune function, noting devastating mortality rates approaching 10,000 deaths nationwide. Dr. Dawn celebrates a breakthrough antibiotic discovery of Lariocidin which works against highly drug-resistant bacteria through novel protein synthesis inhibition. She explains how antibiotic resistance spreads between bacterial species just like social media memes, emphasizing the urgent need for new treatments as 4 million people die annually from resistant infections. Dr. Dawn advocates for public funding since pharmaceutical companies avoid antibiotic development due to poor profit margins. She answers an email about Epstein-Barr virus detection, explaining its role in mononucleosis, Burkitt's lymphoma, and chronic fatigue syndrome. Dr. Dawn describes how EBV can remain dormant and reactivate during stress or immunocompromise, potentially triggering autoimmunity. She discusses similarities between EBV reactivation, Lyme disease, and long COVID, suggesting they may represent variations of the same inflammatory syndrome with different triggers. She explores the nocebo effect - how negative expectations worsen outcomes - and its amplification through social media. Dr. Dawn cites studies showing people warned about erectile dysfunction or altitude headaches experience these symptoms more frequently. She discusses recent phenomena like TikTok-induced tics and vaccine side effect amplification, warning that online health information creates dangerous nocebo loops that spread faster than traditional word-of-mouth.

Matters Microbial #93: Preventing Antibiotic Resistance May 29, 2025 Today's episode was an in-person podcast at the University of Texas Austin!  Dr. Despoina Mavridou, Assistant Professor of Molecular Biosciences, joins the #QualityQuorum to discuss how her research group improves antibiotic effectiveness by impeding protein folding, and why this matters in the fight against antimicrobial resistance. Host: Mark O. Martin Guest: Despoina Mavridou Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode Here is a link to a wonderful video of the #LuxArt by UT-Austin students during my visit. Please give it watch and enjoy the creativity and positive #MicrobialPR. An effective TED talk by science journalist Maryn McKenna describing the threat of AMR in an accessible fashion. A CDC report on the growing threat of AMR. A review article about antibiotics. An overview of how bacteria become resistant to antibiotics.  A very recent review of the cell wall of bacteria—often the target of antibiotics. A video overview of beta-lactam antibiotics and resistance mechanisms. An overview of how protein folding is related to activity of proteins…including AMR gene products. A wonderful article by Dr. Mavridou and coworkers, describing how altering protein folding in bacteria can make them more vulnerable to antibiotics. A less technical version of the above article; well worth your reading. Dr. Mavridou's faculty website. Dr. Mavridou's research group website, which is most interesting. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

Matters Microbial #89: Can AI Point Us to New Antibiotics May 1, 2025 Today, Dr. Amir Mitchell, Associate Professor of Systems Biology at the University of Massachusetts Medical School, joins the #QualityQuorum to discuss using artificial intelligence to develop new and effective antibiotics in our endless battle against drug-resistant microbes. Host: Mark O. Martin Guest: Amir MItchell Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode An article exploring the impact of the microbiome on drug effectiveness. A blog post discussing the relationship between the gut microbiome and creosote metabolism in wood rats. An essay about the threat of antibiotic resistance. A more scholarly article on this topic. A CDC report of the rise of antibiotic resistance. A very moving TED talk on this topic. An overview of antibiotic resistance mechanisms. A video from Dr. Michael Baym's laboratory demonstrating how rapidly antibiotic resistance can occur. An essay discussing the use of artificial intelligence in the search for new antibiotics.  An article from Dr. Mitchell's research group discussing his approach to identity new antimicrobial compounds. Dr. Mitchell's faculty website. Dr. Mitchell's very interesting research team website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

Phage therapy is stepping into the spotlight as antibiotic resistance rises - and Jessica Sacher is helping lead the charge. In this episode, Ross Katz speaks with Jessica, Co-Founder of Phage Directory and Staff Scientist at Stanford, about sourcing phages, operationalizing therapy, and predicting efficacy through data. This conversation explores how personalized phage therapy works, its scalability, and the data challenges shaping its future. ​​What You'll Learn in This Episode: Why phage therapy is a promising solution to antibiotic-resistant infectionsHow Phage Directory connects researchers and clinicians to accelerate treatmentWhat operational hurdles exist in scaling personalized phage productionHow data science is being applied to predict effective phage-bacteria matchesWhy building infrastructure and awareness is essential to adoption in clinical care Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about Phage DirectoryConnect with Jessica on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Resources Mentioned:  Why Language Itself Might Be Holding Back AI – by Ross Katz: https://www.linkedin.com/pulse/why-language-itself-might-holding-back-ai-ross-katz-rcl9e/?trackingId=Y6%2FH45W%2BxImfl%2By2geB6%2Bg%3D%3DBacteriophage Therapy for Multidrug-Resistant Infections – PubMed: https://pubmed.ncbi.nlm.nih.gov/40026251/Cystic Fibrosis Australia and Phage Australia Survey – medRxiv: https://www.medrxiv.org/content/10.1101/2024.05.14.24307275v1Phage Directory: https://phage.directory/

Do you keep relapsing after treating candida, SIBO or other conditions? The culprit behind these never-ending cycles may be biofilms. In this episode, I'll explain how biofilms form, help you identify signs that you have them, and recommend the best antibiofilm agents. Tune in!   Learn more about biofilms and improve your gut now! Reach out to our virtual clinic: https://drruscio.com/virtual-clinic/  

States rush to ban food dyes ahead of federal action; NIH cuts funds for studies of vaccine hesitancy; RFK Jr. ridiculed for urging vitamin A for measles; Brain tumors in firefighters show signature of chemical exposure; Unpacking the causes of numbness, tingling and pain in lower extremities; Class-action lawsuit targets Depo-Provera as contributor to meningioma brain tumors; Uncovering the mystery of Trump's 20+ pound weight loss; Microplastics implicated in spiraling antibiotic resistance.

In this episode of Keeping It Real, Jillian dives into the alarming rise of antibiotic-resistant bacteria and the profound dangers they pose to global health. From the overprescription of antibiotics in humans to their rampant use in factory farming, she explores how these practices are fueling the growth of "superbugs" that traditional medicines can no longer defeat. Jillian also discusses a few key strategies to combat this looming crisis, including responsible antibiotic use, sustainable farming practices, and the power of voting with our dollars. Join her for this hot take about how we can prevent a future where life-saving drugs no longer work.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.